BAKER BROS. ADVISORS LP Q4 2017 Filing
Filed February 14, 2018
Portfolio Value
$11.5B
Holdings
123
Report Date
Q4 2017
Filing Type
13F-HR
All Holdings (123 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | INCYIncyte Corporation | 34,230,523 | $3.2T | 28100.47% | |
| 2 | SGENEURSeattle Genetics, Inc. | 45,725,556 | $2.4T | 21203.96% | |
| 3 | ALXNAlexion Pharmaceuticals, Inc. | 8,553,864 | $1.0T | 8866.69% | |
| 4 | ACADACADIA Pharmaceuticals Inc. | 27,228,338 | $819.8B | 7106.18% | |
| 5 | BMRNBioMarin Pharmaceutical Inc. | 7,583,084 | $676.2B | 5860.96% | |
| 6 | —Genomic Health, Inc. | 13,781,102 | $471.3B | 4085.21% | |
| 7 | ONCBeiGene, Ltd. | 3,849,231 | $376.1B | 3260.33% | |
| 8 | —DBV Technologies S.A. | 5,509,560 | $135.5B | 1174.78% | |
| 9 | —Aquinox Pharmaceuticals, Inc. | 10,934,154 | $128.6B | 1114.55% | |
| 10 | ASNDAscendis Pharma A/S | 2,618,818 | $104.9B | 909.33% | |
| 11 | —Ablynx NV | 4,161,118 | $104.0B | 901.32% | |
| 12 | SG7Sage Therapeutics, Inc. | 616,514 | $101.5B | 880.17% | |
| 13 | AMRNAmarin Corporation plc | 22,669,509 | $90.9B | 787.94% | |
| 14 | —AveXis, Inc. | 775,000 | $85.8B | 743.42% | |
| 15 | NBIXNeurocrine Biosciences, Inc. | 1,004,624 | $77.9B | 675.64% | |
| 16 | ARRYEURArray BioPharma Inc. | 5,656,196 | $72.4B | 627.53% | |
| 17 | —Spark Therapeutics, Inc. | 1,384,130 | $71.2B | 616.90% | |
| 18 | BCRXBioCryst Pharmaceuticals, Inc. | 13,997,172 | $68.7B | 595.70% | |
| 19 | ERYP1EURErytech Pharma S.A. | 3,090,069 | $68.0B | 589.78% | |
| 20 | NVTA1EURInvitae Corporation | 7,288,300 | $66.2B | 573.61% | |
| 21 | ARGXargenx SE | 961,754 | $60.7B | 526.35% | |
| 22 | RYTMRhythm Pharmaceuticals, Inc. | 2,049,020 | $59.5B | 516.12% | |
| 23 | MDGLMadrigal Pharmaceuticals, Inc. | 615,684 | $56.5B | 489.85% | |
| 24 | HRTXHeron Therapeutics, Inc. | 3,060,641 | $55.4B | 480.17% | |
| 25 | MRTXEURMirati Therapeutics, Inc. | 2,549,461 | $46.5B | 403.29% | |
| 26 | EX9Exelixis, Inc. | 1,506,499 | $45.8B | 396.96% | |
| 27 | —Bellicum Pharmaceuticals, Inc. | 5,032,313 | $42.3B | 366.83% | |
| 28 | NVAX 3.75 02/01/23Novavax, Inc. | 88,500,000 | $40.9B | 354.19% | |
| 29 | —Idera Pharmaceuticals, Inc. | 18,315,802 | $38.6B | 334.97% | |
| 30 | —Ignyta, Inc. | 1,384,266 | $37.0B | 320.36% | |
| 31 | —bluebird bio, Inc. | 200,000 | $35.6B | 308.74% | |
| 32 | GBYSangamo Therapeutics, Inc. | 2,113,376 | $34.7B | 300.41% | |
| 33 | CERSCerus Corporation | 9,745,209 | $32.9B | 285.51% | |
| 34 | HALOHalozyme Therapeutics, Inc. | 1,581,424 | $32.0B | 277.71% | |
| 35 | —Abeona Therapeutics Inc. | 1,984,364 | $31.5B | 272.62% | |
| 36 | —Acorda Therapeutics, Inc. | 35,083,000 | $29.8B | 257.87% | |
| 37 | —GW Pharmaceuticals plc | 221,800 | $29.3B | 253.79% | |
| 38 | CBAYUSDCymaBay Therapeutics, Inc. | 2,991,775 | $27.5B | 238.57% | |
| 39 | —Aimmune Therapeutics, Inc. | 673,908 | $25.5B | 220.91% | |
| 40 | GLPGGalapagos NV | 259,894 | $24.4B | 211.21% | |
| 41 | CPRXCatalyst Pharmaceuticals, Inc. | 5,852,153 | $22.9B | 198.33% | |
| 42 | MRUSMerus N.V. | 1,160,014 | $22.5B | 195.06% | |
| 43 | NTLAIntellia Therapeutics, Inc. | 1,145,453 | $22.0B | 190.83% | |
| 44 | IM8NInsmed Incorporated | 700,000 | $21.8B | 189.18% | |
| 45 | XNCRXencor, Inc. | 872,072 | $19.1B | 165.69% | |
| 46 | —Progenics Pharmaceuticals, Inc. | 3,150,808 | $18.7B | 162.49% | |
| 47 | ANABAnaptysBio, Inc. | 181,386 | $18.3B | 158.35% | |
| 48 | AERIEURAerie Pharmaceuticals, Inc. | 299,356 | $17.9B | 155.04% | |
| 49 | IMGNEURImmunoGen, Inc. | 2,563,489 | $16.4B | 142.43% | |
| 50 | —MyoKardia, Inc. | 355,264 | $15.0B | 129.64% | |
| 51 | BMRN 0.599 08/01/24BioMarin Pharmaceutical Inc. | 15,000,000 | $14.9B | 129.39% | |
| 52 | —Foamix Pharmaceuticals Ltd. | 2,466,702 | $14.8B | 128.50% | |
| 53 | ASMBAssembly Biosciences, Inc. | 322,727 | $14.6B | 126.57% | |
| 54 | —BioMarin Pharmaceutical Inc. | 12,228,000 | $13.2B | 114.57% | |
| 55 | NKTREURNektar Therapeutics | 171,934 | $10.3B | 89.00% | |
| 56 | LGNDLigand Pharmaceuticals Incorporated | 73,386 | $10.0B | 87.10% | |
| 57 | —Stemline Therapeutics, Inc. | 633,497 | $9.9B | 85.66% | |
| 58 | RIGLUSDRigel Pharmaceuticals, Inc. | 2,518,882 | $9.8B | 84.71% | |
| 59 | GLYCEURGlycoMimetics, Inc. | 563,312 | $9.5B | 81.98% | |
| 60 | QUREuniQure N.V. | 482,557 | $9.5B | 81.94% | |
| 61 | ITCIEURIntra-Cellular Therapies, Inc. | 609,166 | $8.8B | 76.46% | |
| 62 | —Achillion Pharmaceuticals, Inc. | 2,856,637 | $8.2B | 71.31% | |
| 63 | ALKSAlkermes plc | 150,251 | $8.2B | 71.27% | |
| 64 | —NewLink Genetics Corporation | 1,007,273 | $8.2B | 70.81% | |
| 65 | —Aegerion Pharmaceuticals, Inc. | 9,517,000 | $7.6B | 65.58% | |
| 66 | AGIOAgios Pharmaceuticals, Inc. | 128,666 | $7.4B | 63.76% | |
| 67 | —ContraFect Corporation | 7,153,076 | $7.2B | 62.62% | |
| 68 | XLRNAcceleron Pharma Inc. | 163,900 | $7.0B | 60.29% | |
| 69 | MGNXMacroGenics, Inc. | 363,676 | $6.9B | 59.89% | |
| 70 | VNDAVanda Pharmaceuticals Inc. | 423,884 | $6.4B | 55.85% | |
| 71 | AGLEUSDAeglea BioTherapeutics, Inc. | 1,137,872 | $6.2B | 53.36% | |
| 72 | TTPHEURTetraphase Pharmaceuticals, Inc. | 935,000 | $5.9B | 51.06% | |
| 73 | —Adamas Pharmaceuticals, Inc. | 172,630 | $5.8B | 50.71% | |
| 74 | —Nabriva Therapeutics plc | 938,235 | $5.6B | 48.63% | |
| 75 | —Syros Pharmaceuticals, Inc. | 574,835 | $5.6B | 48.48% | |
| 76 | BDQMAlbireo Pharma, Inc. | 200,000 | $5.1B | 44.38% | |
| 77 | —Spring Bank Pharmaceuticals, Inc. | 373,144 | $5.0B | 43.47% | |
| 78 | —La Jolla Pharmaceutical Company | 154,675 | $5.0B | 43.14% | |
| 79 | —Aevi Genomic Medicine, Inc. | 4,055,142 | $4.9B | 42.18% | |
| 80 | —Clementia Pharmaceuticals Inc. | 250,000 | $4.7B | 41.13% | |
| 81 | CRBPEURCorbus Pharmaceuticals Holdings, Inc. | 660,714 | $4.7B | 40.66% | |
| 82 | —Endocyte, Inc. | 1,087,323 | $4.7B | 40.34% | |
| 83 | —Advanced Accelerator Applications S.A. | 55,125 | $4.5B | 39.00% | |
| 84 | —Acorda Therapeutics, Inc. | 205,966 | $4.4B | 38.29% | |
| 85 | IFRXInflaRx N.V. | 200,000 | $4.2B | 36.32% | |
| 86 | —INOTEK Technologies Corp. | 5,000,000 | $4.0B | 34.75% | |
| 87 | OVIDOvid Therapeutics Inc. | 333,333 | $3.3B | 28.52% | |
| 88 | —Versartis, Inc. | 1,426,310 | $3.1B | 27.20% | |
| 89 | —Akari Therapeutics Plc | 696,901 | $3.0B | 26.16% | |
| 90 | TREURTrillium Therapeutics Inc. | 409,323 | $3.0B | 25.73% | |
| 91 | —Epizyme, Inc. | 232,481 | $2.9B | 25.29% | |
| 92 | SELBUSDSelecta Biosciences, Inc. | 283,716 | $2.8B | 24.12% | |
| 93 | —Sunesis Pharmaceuticals, Inc. | 741,665 | $2.7B | 23.72% | |
| 94 | —Protalix BioTherapeutics, Inc. | 3,423,000 | $2.6B | 22.33% | |
| 95 | NVAXNovavax, Inc. | 2,000,000 | $2.5B | 21.50% | |
| 96 | —Tonix Pharmaceuticals Holdings Corp. | 699,500 | $2.4B | 20.92% | |
| 97 | KRYSKrystal Biotech, Inc. | 200,000 | $2.1B | 18.24% | |
| 98 | KPTIEURKaryopharm Therapeutics Inc. | 216,990 | $2.1B | 18.05% | |
| 99 | NTRANatera, Inc. | 228,676 | $2.1B | 17.82% | |
| 100 | —Trevena, Inc. | 950,000 | $1.5B | 13.17% |
Page 1 of 2Next